BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9359506)

  • 21. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
    van den Heuvel-Eibrink MM; van der Holt B; Burnett AK; Knauf WU; Fey MF; Verhoef GE; Vellenga E; Ossenkoppele GJ; Löwenberg B; Sonneveld P
    Ann Hematol; 2007 May; 86(5):329-37. PubMed ID: 17340137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression.
    Goellner S; Steinbach D; Schenk T; Gruhn B; Zintl F; Ramsay E; Saluz HP
    Eur J Cancer; 2006 Nov; 42(16):2807-14. PubMed ID: 16978861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics.
    Martínez A; San Miguel JF; Valverde B; Bárez A; Moro MJ; García-Marcos MA; Pérez-Simón JA; Vidriales B; Orfao A
    Ann Hematol; 1997 Sep; 75(3):81-6. PubMed ID: 9368475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
    Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
    Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance factors in acute myeloid leukemia: a comparative analysis.
    Filipits M; Stranzl T; Pohl G; Heinzl H; Jäger U; Geissler K; Fonatsch C; Haas OA; Lechner K; Pirker R
    Leukemia; 2000 Jan; 14(1):68-76. PubMed ID: 10637479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.
    Lamy T; Drenou B; Grulois I; Fardel O; Jacquelinet C; Goasguen J; Dauriac C; Amiot L; Bernard M; Fauchet R
    Leukemia; 1995 Sep; 9(9):1549-55. PubMed ID: 7658724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
    Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
    Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia.
    Del Poeta G; Venditti A; Stasi R; Aronica G; Cox MC; Buccisano F; Tamburini A; Bruno A; Maurillo L; Battaglia A; Suppo G; Epiceno AM; Del Moro B; Masi M; Amadori S; Papa G
    Leuk Res; 1999 May; 23(5):451-65. PubMed ID: 10374859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
    Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
    Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
    Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
    Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
    J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein expression in de novo acute myeloid leukemia.
    Del Poeta G; Venditti A; Aronica G; Stasi R; Cox MC; Buccisano F; Bruno A; Tamburini A; Suppo G; Simone MD; Epiceno AM; Del Moro B; Masi M; Papa G; Amadori S
    Leuk Lymphoma; 1997 Oct; 27(3-4):257-74. PubMed ID: 9402325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
    Suárez L; Vidriales MB; Moreno MJ; López A; García-Laraña J; Pérez-López C; Tormo M; Lavilla E; López-Berges MC; de Santiago M; San Miguel JF; Orfao A;
    Haematologica; 2005 Jan; 90(1):54-9. PubMed ID: 15642669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression.
    Legrand O; Perrot JY; Simonin G; Baudard M; Cadiou M; Blanc C; Ramond S; Viguié F; Marie JP; Zittoun R
    Br J Haematol; 1998 Jan; 100(1):147-55. PubMed ID: 9450804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukaemia cell drug resistance and prognostic factors in AML.
    Nørgaard JM; Olesen G; Kristensen JS; Pedersen B; Hokland P
    Eur J Haematol; 1999 Oct; 63(4):219-24. PubMed ID: 10530409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia.
    Chisini M; Stefanizzi C; Ceglie T; Raponi S; Vozella F; Colafigli G; Salaroli A; D'Angiò M; Mancini M; Diverio D; Breccia M; Mancini F; Minotti C; Trisolini S; Capria S; Testi AM; Guarini A; Latagliata R; De Propris MS; Foà R
    Hematol Oncol; 2017 Dec; 35(4):804-809. PubMed ID: 27400753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy.
    Kasimir-Bauer S; Ottinger H; Meusers P; Beelen DW; Brittinger G; Seeber S; Scheulen ME
    Exp Hematol; 1998 Nov; 26(12):1111-7. PubMed ID: 9808049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome.
    Schaich M; Harbich-Brutscher E; Pascheberg U; Mohr B; Soucek S; Ehninger G; Illmer T
    Haematologica; 2002 May; 87(5):455-64. PubMed ID: 12010657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.